Should I drop my Oramed Pharmaceuticals (NASDAQ:ORMP) position?
 | By Vlad Skutelnik | Macroaxis Story |
My story will recap Oramed Pharmaceuticals. We will evaluate why we are still confident in anticipation of a recovery. Oramed Pharmaceuticals is now traded for 5.53. The entity has historical hype elasticity of 1.42. The average price elasticity to hype of competition is about 1.44. The firm is estimated to increase in value after the next headline, with the price going to jump to 6.95. The recent volatility of media hype impact on the company stock price is is way over 100 percent making price predictions on social media along less reliable. The price boost on the next news is estimated to be 25.68%, whereas the daily expected return is now at 1.51%. The volatility of related hype on Oramed Pharmaceuticals is about 728.51% with expected price after next announcement by competition of 6.97 Given the investment horizon of 30 days the next estimated press release will be in about 6 days.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
Oramed Pharmaceuticals holds a performance score of 15 on a scale of zero to a hundred. The company holds a Beta of -0.7031, which implies possible diversification benefits within a given portfolio. Let's try to break down what Oramed's beta means in this case. As returns on the market increase, returns on owning Oramed Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Oramed Pharmaceuticals is likely to outperform the market. Although it is essential to pay attention to Oramed Pharmaceuticals current trending patterns, it is also good to be reasonable about what you can do with equity existing price patterns. Our philosophy towards forecasting future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Oramed Pharmaceuticals expected return of 1.51 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use Oramed Pharmaceuticals maximum drawdown, and the relationship between the information ratio and expected short fall to analyze future returns on Oramed Pharmaceuticals. The successful prediction of Oramed Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Oramed Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Oramed Pharmaceuticals based on Oramed Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Oramed Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Oramed Pharmaceuticals's related companies.
A focus of Oramed Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Oramed Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...
Use Technical Analysis to project Oramed expected Price
Oramed Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Oramed Pharmaceuticals Gross Profit
Oramed Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Oramed Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Oramed Pharmaceuticals Gross Profit growth over the last 10 years. Please check Oramed Pharmaceuticals' gross profit and other fundamental indicators for more details.
Breaking it down
This firm reported the previous year's revenue of 2.71 M. Net Loss for the year was (14.54 M) with profit before overhead, payroll, taxes, and interest of 2.71 M.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Oramed Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.